ReviewJGH open : an open access journal of gastroenterology and hepatology2025
Glucagon-Like Peptide-2 (GLP-2) Analogues in Patients With Short Bowel Syndrome Dependent on Parenteral Support: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Review in JGH open : an open access journal of gastroenterology and hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Glucagon-Like Peptide-2 (GLP-2) Analogues in Patients With Short Bowel Syndrome Dependent on Parenteral Support: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.JGH open : an open access journal of gastroenterology and hepatology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Short bowel syndrome (SBS) is a malabsorptive condition often requiring long-term parenteral support (PS), which is associated with significant complications. Glucagon-like peptide-2 (GLP-2) analogues are shown to enhance intestinal adaptation and reduce PS dependency. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of GLP-2 analogues in adult patients with SBS dependent on PS. Methods: A systematic search of CENTRAL, PubMed, Embase, ClinicalTrials.gov, and Google Scholar was conducted from inception till May 2025. We included randomized controlled trials (RCTs) comparing GLP-2 analogues with placebo in adult SBS patients on stable PS. We analyzed the outcomes using RevMan 5.4, with risk ratio (RR) and mean differences (MD) as the effect measures. Results: Six RCTs comprising 454 patients were included. GLP-2 analogues significantly reduced PS volume (MD: -251.51 mL/day; 95% CI: -363.93 to -139.08; Conclusion: Our meta-analysis found that GLP-2 analogues are effective in reducing PS volume in patients with SBS who are dependent on PS, without an increase in adverse events. However, the current evidence is limited by a small number of early clinical trials, heterogeneity in dosing regimens, and a paucity of data on newer agents like glepaglutide. Further large-scale phase 3 RCTs are needed to validate the safety and efficacy of GLP-2 analogues before they can be adopted for routine clinical practice.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.